Innoblative Announces Successful First-in-Human Use of its Novel Electrosurgical Device for Breast Cancer Treatment

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Innoblative-SIRA

More Like This

ONWARD® Medical Announces Third Implant of Brain-Computer Interface (BCI) System to Restore Movement after Spinal Cord Injury

Image caption: INBRAIN Cortical BCI; Image credit: INBRAIN Neuroelectronics

INBRAIN Neuroelectronics Announces World’s First Human Graphene-Based Brain Computer Interface Procedure

Dr. Mariana-Felicia Sandor, first author of the SHIELD study: Reoperation Rate in Breast-Conserving Surgery using Confocal Histolog® Scanner for Intraoperative Tissue Assessment, performs real-time, high-resolution tissue assessments during breast-conserving surgery (BCS) using the FDA-cleared Histolog Scanner. SHIELD study data indicates the innovative imaging device reduced reoperation rates during BCS from 30% to 10%, representing a 67% reduction. (Photo: Business Wire)

SamanTree Medical Highlights Research Showing 67% Reduction in Reoperation Rates for Breast-Conserving Surgery at the 2024 SABCS

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

PR Newswire associated0

ClearCut Medical Announces Results of a Post Marketing ClearCoast™ Study Presented at the San Antonio Breast Cancer Symposium

Business Wire logo

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

Pulsecare Medical's nsPFA clinical trial receives satisfactory short-term follow-up results

Pulsecare Medical's nsPFA clinical trial receives satisfactory short-term follow-up results